News

• Yitahome Launches 'The Extraordinary Weeks' Exclusive Holiday Sales for Thanksgiving, Black Friday, Cyber Monday, and Christmas

  

  LOS ANGELES,Nov. 21,2024-- This holiday season,Yitahome invites you to redefine your space and make every moment count with #TheExtraordinaryWeeks campaign. From Thanksgiving to Christmas,enjoy aline-

  11-21

  Details

• Global Witness to the 'Latin American Moment'APEC Summit enhances the reputation of the Asia-Pacific region's collaborative efforts

  

  11-21

  Details

• BuzzCast Short Video Contest Concludes Successfully, Honoring the Five Grand Winners

  

  11-21

  Details

• The factory building project of the second phase of Fujian Three Gorges Offshore Wind Power Industrial Park passed completion acceptance

  

  The factory building project of the second phase of Fujian Three Gorges Offshore Wind Power Industrial Park passed completion acceptance

  11-21

  Details

• RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development

  

  BEIJING,Nov. 19,2024-- With the support of the RiDYMO® platform,we are able to comprehensively explore various potential targets in drug development,including protein-protein interactions,kinases,

  11-20

  Details

• Colt Data Centre Services and RMZ announce a joint venture to invest $1.7 Billion in the Indian Data Centre market

  

  The investment will initially focus on expediting development at existing sites inNavi Mumbai and Ambattur,Chennai,with an additional third site to be added in future.

  11-20

  Details

• Pop Culture Announces Improvement in Overall Operations During the Fiscal Year Ended June 30, 2024

  

  XIAMEN,China,Nov. 19,2024-- In the fiscal year ended June 30,2024,POP CULTURE GROUP CO.,LTD. ("Pop Culture," or the "Company," Nasdaq: CPOP) continued to focus on its three busines

  11-20

  Details

• Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

  

  48-week end-of-treatment data from theongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα

  11-20

  Details

• Neo4j Surpasses $200M in Revenue, Accelerates Leadership in GenAI-Driven Graph Technology

  

  Database pioneer continues to scale at $2B+ valuation as GenAI accelerates demand SAN MATEO,Calif.,Nov. 19,2024--Neo4j®,the world\'s leading graph database and analytics company,announced that it

  11-20

  Details

• Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

  

  NANTONG and SUZHOU,China,Nov. 19,2024-- Ractigen Therapeutics,a clinical-stage pharmaceutical company dedicated to developing innovative therapies,today announced that the U.S. Food and Drug Administr

  11-20

  Details